Literature DB >> 19419803

Antiproliferative activity of arborescidine alkaloids and derivatives.

Leonardo S Santos1, Cristina Theoduloz, Ronaldo A Pilli, Jaime Rodriguez.   

Abstract

Current issues in cancer research involve searching for novel anticancer compounds that can be used to regulate the cell cycle and lead to more effective treatments of tumors. In this study, it was hypothesized that possessing a cyclic alkaloid similar to harmine, arborescidines can disrupt the proliferative state of cancer cells and block the activity of topoisomerases. The antiproliferative activity of arborescidines A-C and their derivatives was evaluated in vitro against four human tumor cell lines: gastric adenocarcinoma, lung cancer, bladder carcinoma and leukemia. Assuming the mechanism of action by topoisomerase II binding model, the compounds possessing the greatest activity had nonpolar side-chain into hydrophobic binding region on the DNA/topo II complex.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19419803     DOI: 10.1016/j.ejmech.2009.04.005

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  3 in total

1.  Dual targeting of microtubule and topoisomerase II by α-carboline derivative YCH337 for tumor proliferation and growth inhibition.

Authors:  Jun-Mei Yi; Xiao-Fei Zhang; Xia-Juan Huan; Shan-Shan Song; Wei Wang; Qian-Ting Tian; Yi-Ming Sun; Yi Chen; Jian Ding; Ying-Qing Wang; Chun-Hao Yang; Ze-Hong Miao
Journal:  Oncotarget       Date:  2015-04-20

2.  Enzymatic Strategy for the Resolution of New 1-Hydroxymethyl Tetrahydro-β-carboline Derivatives in Batch and Continuous-Flow Systems.

Authors:  Rita Megyesi; Enikő Forró; Ferenc Fülöp
Journal:  ChemistryOpen       Date:  2016-03-01       Impact factor: 2.911

Review 3.  Indole-Based Small Molecules as Potential Therapeutic Agents for the Treatment of Fibrosis.

Authors:  Rui Qin; Qian Zhao; Bo Han; Hong-Ping Zhu; Cheng Peng; Gu Zhan; Wei Huang
Journal:  Front Pharmacol       Date:  2022-02-16       Impact factor: 5.810

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.